This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajam, G.
Right arrow Articles by Romero-Steiner, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajam, G.
Right arrow Articles by Romero-Steiner, S.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, September 2007, p. 1223-1227, Vol. 14, No. 9
1071-412X/07/$08.00+0     doi:10.1128/CVI.00184-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Functional Antibodies to the O-Acetylated Pneumococcal Serotype 15B Capsular Polysaccharide Have Low Cross-Reactivities with Serotype 15C{triangledown}

Gowrisankar Rajam, George M. Carlone, and Sandra Romero-Steiner*

Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Received 1 May 2007/ Returned for modification 4 June 2007/ Accepted 20 June 2007

The 23-valent pneumococcal polysaccharide (Ps) vaccine offer protection against vaccine serotypes, but its cross-protection against vaccine-related serotypes is variable. We have demonstrated that the functional antibodies to serotype 15B are specific to the O-acetylated 15B-Ps and that they have low cross-reactivity with serotype 15C. Demonstration of functionally cross-reactive antibodies to vaccine-related serotypes is important for surveillance and vaccine development.

* Corresponding author. Mailing address: MS A-36, Immunology Section, Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333. Phone: (404) 639-2473. Fax: (404) 639-4518. E-mail: SSteiner{at}cdc.gov

{triangledown} Published ahead of print on 3 July 2007.

Clinical and Vaccine Immunology, September 2007, p. 1223-1227, Vol. 14, No. 9
1071-412X/07/$08.00+0     doi:10.1128/CVI.00184-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Melnick, N., Rajam, G., Carlone, G. M., Sampson, J. S., Ades, E. W. (2009). Evaluation of a Novel Therapeutic Approach to Treating Severe Pneumococcal Infection Using a Mouse Model. CVI 16: 806-810 [Abstract] [Full Text]  
  • Zartler, E. R., Porambo, R. J., Anderson, C. L., Chen, L. H., Yu, J., Nahm, M. H. (2009). Structure of the Capsular Polysaccharide of Pneumococcal Serotype 11A Reveals a Novel Acetylglycerol That Is the Structural Basis for 11A Subtypes. J. Biol. Chem. 284: 7318-7329 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»